AGP Picks
View all

Today in Medicine
Provided by AGP

Today in Medicine: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today in Medicine.

August 2026

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31

September 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30

October 2026

Mo Tu We Th Fr Sa Su
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31

Press releases published on September 30, 2026

Italfarmaco Presents New Givinostat (Duvyzat®) Clinical Data Supporting Preservation of Upper Limb Function in Duchenne Muscular Dystrophy Patients at the 2026 World Muscle Society Congress
Sep. 30, 2026

Italfarmaco Presents New Givinostat (Duvyzat®) Clinical Data Supporting Preservation of Upper Limb Function in Duchenne Muscular Dystrophy Patients at the 2026 World Muscle Society Congress

Indeterminate GlobeNewswire
ENT & Allergy Associates Expands Pennsylvania Footprint with Melissa Schwartz, DO, and New Elkins Park Clinical Site
Sep. 30, 2026

ENT & Allergy Associates Expands Pennsylvania Footprint with Melissa Schwartz, DO, and New Elkins Park Clinical Site

Indeterminate GlobeNewswire
Hummingbird Bioscience Announces First Patient Dosed in Phase II Trial of HMBD-001 and Cetuximab in Advanced Squamous Cell Cancers
Sep. 30, 2026

Hummingbird Bioscience Announces First Patient Dosed in Phase II Trial of HMBD-001 and Cetuximab in Advanced Squamous Cell Cancers

Indeterminate GlobeNewswire
Terumo Neuro Signs Agreement to Acquire Arsenal Medical – Advancing Next-Generation Liquid Embolic Innovation for Treating Chronic Subdural Hematoma (cSDH)
Sep. 30, 2026

Terumo Neuro Signs Agreement to Acquire Arsenal Medical – Advancing Next-Generation Liquid Embolic Innovation for Treating Chronic Subdural Hematoma (cSDH)

Indeterminate GlobeNewswire
AnaCardio raises €62.5 million Series B financing to advance transformational novel therapy in heart failure towards Phase 3 readiness
Sep. 30, 2026

AnaCardio raises €62.5 million Series B financing to advance transformational novel therapy in heart failure towards Phase 3 readiness

Indeterminate GlobeNewswire
Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering
Sep. 30, 2026

Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering

Indeterminate GlobeNewswire
Egle Therapeutics Announces Positive Phase 1 Data for EGL-003, Showing Favorable Safety and Selective Treg Expansion in Healthy Volunteer Study
Sep. 30, 2026

Egle Therapeutics Announces Positive Phase 1 Data for EGL-003, Showing Favorable Safety and Selective Treg Expansion in Healthy Volunteer Study

Indeterminate GlobeNewswire
Santhera Pharmaceuticals Halbjahresergebnisse für die sechs Monate bis zum 30. Juni 2026
Sep. 30, 2026

Santhera Pharmaceuticals Halbjahresergebnisse für die sechs Monate bis zum 30. Juni 2026

Indeterminate GlobeNewswire
Santhera Pharmaceuticals Half Year Results for the six months ending 30 June 2026
Sep. 30, 2026

Santhera Pharmaceuticals Half Year Results for the six months ending 30 June 2026

Indeterminate GlobeNewswire
Navigator Medicines Presents New Data at EADV 2026 as Bispecific Antibody Program Advances at Speed in Hidradenitis Suppurativa
Sep. 30, 2026

Navigator Medicines Presents New Data at EADV 2026 as Bispecific Antibody Program Advances at Speed in Hidradenitis Suppurativa

Indeterminate GlobeNewswire
Byron Medical Announces the Product Release of ZUMAX Surgical Microscopes: Setting a New Standard of Advanced Precision Dentistry
Sep. 30, 2026

Byron Medical Announces the Product Release of ZUMAX Surgical Microscopes: Setting a New Standard of Advanced Precision Dentistry

Indeterminate GlobeNewswire

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Today in Medicine

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.